Clinical trials have validated the antitumor efficacy of Flt3L, in which a phase I clinical study reported that injection of an adenoviral vector expressing herpes simplex virus thymidine kinase (HSV-TK) and Flt3L into the tumor cavity of resectable malignant gliomas induced effective antitumor immune responses, resulting in the generation of antitumor memory and new antigen recognition capabilities. Here, FLT3LG is linked to malignant glioma.